2. Search Result
Search Result
Results for "

DNA-PK kinase

" in MedChemExpress (MCE) Product Catalog:

27

Inhibitors & Agonists

1

Screening Libraries

1

Peptides

6

Antibodies

2

Oligonucleotides

1

GMP Molecules

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-10108
    LY294002
    Maximum Cited Publications
    1120 Publications Verification

    		 PI3K Casein Kinase DNA-PK Apoptosis Autophagy Infection Cancer
    LY294002 is a broad-spectrum inhibitor of PI3K with IC50s of 0.5, 0.57, and 0.97 μM for PI3Kα, PI3Kδ and PI3Kβ, respectively . LY294002 also inhibits CK2 with an IC50 of 98 nM . LY294002 is a competitive DNA-PK inhibitor that binds reversibly to the kinase domain of DNA-PK with an IC50 of 1.4 μM. LY294002 is an apoptosis activator .
    LY294002
  • HY-101570
    Nedisertib
    25+ Cited Publications

    Peposertib; M3814

    		 DNA-PK BCRP Cancer
    Nedisertib (Peposertib) is an orally active selective DNA-dependent protein kinase (DNA-PK) inhibitor with an IC50 value of less than 3 nM. Nedisertib also acts as a modulator of ABCG2, capable of reversing ABCG2-mediated multidrug resistance (MDR), thus providing new strategies for combination therapy. By inhibiting DNA double-strand break repair, Nedisertib can enhance the efficacy of chemotherapy and radiotherapy. Nedisertib exhibits antitumor activity .
    Nedisertib
  • HY-139609
    Camonsertib
    2 Publications Verification

    RP-3500; ATR inhibitor 4

    		 ATM/ATR mTOR Cancer
    Camonsertib (RP-3500) is an orally active, selective ATR kinase inhibitor (ATRi) with an IC50 of 1.00 nM in biochemical assays. Camonsertib shows 30-fold selectivity for ATR over mTOR (IC50=120 nM) and >2,000-fold selectivity over ATM, DNA-PK, and PI3Kα kinases. Camonsertib has potent antitumor activity .
    Camonsertib
  • HY-16962
    CC-115
    2 Publications Verification

    		 DNA-PK mTOR Cancer
    CC-115 is a potent and dual DNA-PK and mTOR kinase inhibitor with IC50s of 13 nM and 21 nM, respectively. CC-115 blocks both mTORC1 and mTORC2 signaling.
    CC-115
  • HY-16962A
    CC-115 hydrochloride
    2 Publications Verification

    		 DNA-PK mTOR Cancer
    CC-115 hydrochloride is a potent and dual DNA-PK and mTOR kinase inhibitor with IC50s of 13 nM and 21 nM, respectively. CC-115 blocks both mTORC1 and mTORC2 signaling.
    CC-115 hydrochloride
  • HY-132293
    BAY-8400
    3 Publications Verification

    		 DNA-PK Cancer
    BAY-8400 is an orally active, potent and selective DNA-dependent protein kinase (DNA-PK) inhibitor (IC50=81 nM). BAY-8400 can be used for the research of cancer .
    BAY-8400
  • HY-16124
    Canfosfamide

    TLK-286; TER286

    		 DNA-PK Apoptosis Cancer
    Canfosfamide (TLK-286, TER286) is a glutathione analogue prodrug that is activated by glutathione S-transferase P1-1 and induces apoptosis. Canfosfamide also inhibits the catalytic kinase activity of DNA-dependent protein kinase (DNA-PK). Canfosfamide produces an anticancer alkylating agent and a glutathione derivative after activation. Canfosfamide can be used to research malignancies .
    Canfosfamide
  • HY-15268
    PP487

    		c-Met/HGFR PI3K DNA-PK mTOR Bcr-Abl Src VEGFR EGFR PDGFR Cancer
    PP487 is a selective dual inhibitor of Tyrosine kinase/PI3-K, with IC50 values of 0.017 μM, 0.072 μM, 0.004 μM, 0.01 μM, 0.55 μM, 0.22 μM, and < 0.01 μM against DNA-PK, mTOR, Hck, Src, EGFR, EphB4, and PDGFR, respectively. PP487 can be used in cancer research .
    PP487
  • HY-146565
    DNA-PK-IN-8

    		DNA-PK Cancer
    DNA-PK-IN-8 is a highly potent, selective and orally active DNA-dependent protein kinase (DNA-PK) inhibitor with an IC50 value of 0.8 nM. DNA-PK-IN-8 exhibits synergistic antiproliferative activity against a series of cancer cell lines and significantly suppresses HL-60 tumor growth, when using in combination with Doxorubicin .
    DNA-PK-IN-8
  • HY-100707
    IC 86621

    		DNA-PK Apoptosis Inflammation/Immunology Cancer
    IC 86621 is a potent DNA-dependent protein kinase (DNA-PK) inhibitor, with an IC50 of 120 nM. IC 86621 also acts as a selective and reversible ATP-competitive inhibitor.IC 86621 inhibits DNA-PK mediated cellular DNA double-strand break (DSB) repair (EC50=68 µM). IC 86621 increases DSB-induced antitumor activity without cytotoxic effects. IC 86621 can protects rheumatoid arthritis (RA) T cells from apoptosis .
    IC 86621
  • HY-101570G
    Nedisertib

    Peposertib; M3814

    		 DNA-PK BCRP Cancer
    Nedisertib (GMP) (Peposertib (GMP)) is Nedisertib (HY-101570) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Nedisertib is an orally active selective DNA-dependent protein kinase (DNA-PK) inhibitor with an IC50 value of less than 3 nM. Nedisertib also acts as a modulator of ABCG2, capable of reversing ABCG2-mediated multidrug resistance (MDR), thus providing new strategies for combination therapy. By inhibiting DNA double-strand break repair, Nedisertib can enhance the efficacy of chemotherapy and radiotherapy. Nedisertib exhibits antitumor activity .
    Nedisertib
  • HY-177631A
    Etidaligide sodium

    DT01 sodium; coDbait sodium

    		 Poly(ADP-ribose) Glycohydrolase (PARG) Cancer
    Etidaligide sodium, an AsiDNA, a first-in-class DNA repair inhibitor designed to prevent the repair of DNA damage in tumour cells. It also activates DNA-dependent protein kinase (DNA-PK) and poly (ADP-ribose) polymerase enzymes that induce phosphorylation
    Etidaligide sodium
  • HY-177631
    Etidaligide

    DT01; coDbait

    		 Poly(ADP-ribose) Glycohydrolase (PARG) Cancer
    Etidaligide, an AsiDNA, a first-in-class DNA repair inhibitor designed to prevent the repair of DNA damage in tumour cells. It also activates DNA-dependent protein kinase (DNA-PK) and poly (ADP-ribose) polymerase enzymes that induce phosphorylation of H2A
    Etidaligide
  • HY-147567
    ATR-IN-15

    		ATM/ATR DNA-PK PI3K Cancer
    ATR-IN-15 (compound 1) is an orally active and potent ATR kinase inhibitor, with an IC50 of 8 nM. ATR-IN-15 also inhibits human colon tumor cells LoVo, DNA-PK and PI3K, with IC50 values of 47, 663 and 5131 nM, respectively .
    ATR-IN-15
  • HY-10108R
    LY294002 (Standard)

    		Reference Standards PI3K Casein Kinase DNA-PK Apoptosis Autophagy Infection Cancer
    LY294002 (Standard) is the analytical standard of LY294002. This product is intended for research and analytical applications. LY294002 is a broad-spectrum inhibitor of PI3K with IC50s of 0.5, 0.57, and 0.97 μM for PI3Kα, PI3Kδ and PI3Kβ, respectively . LY294002 also inhibits CK2 with an IC50 of 98 nM . LY294002 is a competitive DNA-PK inhibitor that binds reversibly to the kinase domain of DNA-PK with an IC50 of 1.4?μM. LY294002 is an apoptosis activator .
    LY294002 (Standard)
  • HY-142944
    DNA-PK-IN-2

    		DNA-PK Cancer
    DNA-PK-IN-2 is a potent inhibitor of DNA-PK. DNA-dependent protein kinase (DNA-PK) is a DNA-PK enzyme complex composed of Ku70/Ku80 heterodimer and DNA-dependent protein kinase catalytic subunit (DNA-PKcs). DNA-PK-IN-2 has the potential for the research of cancer diseases (extracted from patent WO2021136462A1, compound 1) .
    DNA-PK-IN-2
  • HY-142943
    DNA-PK-IN-1

    		DNA-PK Cancer
    DNA-PK-IN-1 is a potent inhibitor of DNA-PK. DNA-dependent protein kinase (DNA-PK) is a DNA-PK enzyme complex composed of Ku70/Ku80 heterodimer and DNA-dependent protein kinase catalytic subunit (DNA-PKcs). DNA-PK-IN-1 has the potential for the research of cancer diseases (extracted from patent WO2021136463A1, compound 1) .
    DNA-PK-IN-1
  • HY-146566
    DNA-PK-IN-9

    		DNA-PK Cancer
    DNA-PK-IN-9 (compound YK6) is a potent DNA-dependent protein kinase (DNA-PK) inhibitor with an IC50 value of 10.47 nM. DNA-PK-IN-9 can be used for researching anticancer .
    DNA-PK-IN-9
  • HY-114923
    SU-11752

    		DNA-PK PI3K Cancer
    SU-11752 is an inhibitor for DNA-dependent protein kinase (DNA-PK) with an IC50 of 0.13 μM. SU-11752 inhibits PI3K p110γ kinase with IC50 of 1.1 μM. SU-11752 binds competitively for ATP-site in DNA-PK, results in inhibition of intracellular DNA double-strand break repair and increases the sensitivity of cells to radiotherapy .
    SU-11752
  • HY-108975
    OK-1035

    		DNA-PK Others
    OK-1035 is a selective DNA-dependent protein kinase (DNA-PK) inhibitor with an IC50 of 100 μM .
    OK-1035
  • HY-122176
    NU-7107

    		Drug Derivative DNA-PK Cancer
    NU-7107 is a derivative of NU7026 (HY-15719) and a DNA-dependent protein kinase (DNA-PK) inhibitor with an IC50 >10 μM. NU-7107 is applicable for cancer research .
    NU-7107
  • HY-172771
    Multi-target kinase inhibitor 4

    		PI3K DNA-PK P-glycoprotein Cancer
    Multi-target kinase inhibitor 4 (Compound 2) is a PI3K/DNA-PK inhibitor and potent chemosensitizer that can increase the amount of DNA double strand breaks induced by Doxorubicin (HY-15142A). Multi-target kinase inhibitor 4, is an efficient inhibitor of multidrug resistance (MDR) that exhibits inhibitory activity toward P-glycoprotein-mediated drug efflux. Multi-target kinase inhibitor 4 can be loaded into PEG-coated LNPs .
    Multi-target kinase inhibitor 4
  • HY-181848
    DNA-PK-IN-16

    		DNA-PK Apoptosis Cancer
    DNA-PK-IN-16 is an orally active DNA-dependent protein kinase (DNA-PK) inhibitor with an IC50 of 10.2 nM. DNA-PK-IN-16 induces the upregulation of γH2A.X, a biomarker of DNA double-strand breaks. DNA-PK-IN-16 exhibits antiproliferative activity in various cancer cell lines. DNA-PK-IN-16 enhances the infiltration of CD8 + T cells in tumor tissues through synergistic action with anti-PD-L1 monoclonal antibody. DNA-PK-IN-16 is applicable for cancer research .
    DNA-PK-IN-16
  • HY-101570R
    Nedisertib (Standard)

    Peposertib (Standard); M3814 (Standard)

    		 DNA-PK Reference Standards BCRP Cancer
    Nedisertib (Standard) is the analytical standard of Nedisertib (HY-101570). This product is intended for research and analytical applications. Nedisertib (Peposertib) is an orally active selective DNA-dependent protein kinase (DNA-PK) inhibitor with an IC50 value of less than 3 nM. Nedisertib also acts as a modulator of ABCG2, capable of reversing ABCG2-mediated multidrug resistance (MDR), thus providing new strategies for combination therapy. By inhibiting DNA double-strand break repair, Nedisertib can enhance the efficacy of chemotherapy and radiotherapy. Nedisertib exhibits antitumor activity .
    Nedisertib (Standard)
  • HY-172247
    ATR-IN-31

    		ATM/ATR Cancer
    ATR-IN-31 is a selective ATR kinase inhibitor with an IC50 of 7 nM. ATR-IN-31 does not significantly inhibit ATM kinase activity. ATR-IN-31 inhibits viability of prostate cancer cells.ATR-IN-31 can be used for the research of prostate cancer .
    ATR-IN-31
  • HY-182017
    ATR ligand 2

    		Ligands for Target Protein for PROTAC ATM/ATR Others
    ATR ligand 2 (Compound 26) is a ATR PROTAC ligand. ATR ligand 2 can be conjugated with E3 ligase Ligand (HY-W077589A) and linker to synthesize PROTAC ATR degrader-3 (HY-182016) .
    ATR ligand 2
  • HY-181786
    ATM-IN-13

    		ATM/ATR Cancer
    ATM-IN-13 (A36) is an orally active, selective ATM kinase inhibitor with a human IC50 of 0.3 nM. ATM-IN-13 blocks the ATM-mediated DNA double-strand break repair signaling pathway, reduces the phosphorylation levels of ATM and p53, and inhibits ATM-dependent DNA damage response. ATM-IN-13 can be used in the research of colorectal cancer .
    ATM-IN-13

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: